je.st
news
Tag: therapeutics
Cytori Therapeutics Closes Previously Announced $10 Million Offering
2014-06-07 03:44:28| Biotech - Topix.net
Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells to treat cardiovascular disease and other medical conditions.
Tags: million
previously
offering
announced
PTC Therapeutics Receives Positive Opinion From CHMP For Translarna (ataluren)
2014-06-04 13:02:23| drugdiscoveryonline News Articles
PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that following its request for re-examination, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the company's application for a conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older
Tags: positive
opinion
receives
therapeutics
PsiOxus Therapeutics Announces Positive Study Results of Oncolytic...
2014-06-03 13:42:23| Logistics - Topix.net
OXFORD, England & CHICAGO -- -- PsiOxus Therapeutics, Ltd. , an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international multicentre clinical program of the oncolytic vaccine enadenotucirev were presented at the 2014 American Society of Clinical Oncology Annual ... (more)
Tags: results
study
positive
announces
Cell Therapeutics, Inc. Announces Change Of Name To
2014-05-31 04:35:27| Biotech - Topix.net
"From the beginning, CTI has looked at potential therapies from the patient's perspective to address both the clinical need and the impact treatment can have on a patient's life.
Tags: to
change
cell
announces
PsiOxus Therapeutics to Release Study Results of Oncolytic Vaccine Enadenotucirev in Cancer Patients
2014-05-21 18:54:23| Logistics - Topix.net
The EVOLVE trial is a phase I/II trial of intravenous administration of enadenotucirev to patients with epithelial cancers and the MoA trial is a phase I "window of opportunity" trial evaluating intravenous and intra-tumoural administration of enadenotucirev to patients with colon cancer.
Tags: results
study
release
cancer
Sites : [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] next »